Human Papillomavirus-positive Oropharyngeal Cancer - Pipeline Insight, 2024

This Human Papillomavirus-positive Oropharyngeal Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Human Papillomavirus-positive Oropharyngeal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Human Papillomavirus-positive Oropharyngeal Cancer Understanding

Human Papillomavirus-positive Oropharyngeal Cancer: Overview

Head-and-neck squamous cell carcinomas include cancers of the oral cavity, larynx, hypopharynx, and oropharynx1. The oropharynx comprises the tonsils and the base of the tongue. Despite a steady decline in the incidence of head- and-neck cancers in the last few decades, the incidence of oropharyngeal cancer (opc) has shown an overall increase that is largely attributable to the rise in infections with the human papillomavirus (hpv). Head-and-neck cancer remains a relatively rare disease, accounting for only 5% of cancers worldwide. As a result, knowledge of the disease, the consequences of treatment, and patient needs after treatment are less widespread.

Human Papillomavirus-positive Oropharyngeal Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human Papillomavirus-positive Oropharyngeal Cancer pipeline landscape is provided which includes the disease overview and Human Papillomavirus-positive Oropharyngeal Cancer treatment guidelines. The assessment part of the report embraces, in depth Human Papillomavirus-positive Oropharyngeal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human Papillomavirus-positive Oropharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Human Papillomavirus-positive Oropharyngeal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Human Papillomavirus-positive Oropharyngeal Cancer.

This segment of the Human Papillomavirus-positive Oropharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Human Papillomavirus-positive Oropharyngeal Cancer Drugs
Mupadolimab: Corvus Pharmaceuticals Mupadolimab (CPI-006) is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. While there are other anti-CD73 antibodies and small molecules in development for treatment of cancer, such agents react with a different region of CD73. Mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine. Mupadolimab is being studied in combination with pembrolizumab in a Phase 1/1b study in patients with advanced HPV+ (human papilloma virus) head and neck cancers. It is postulated that the activation of B cells will enhance immunity to viral antigens within the tumors of these patients, leading to improved clinical outcomes.

Human Papillomavirus-positive Oropharyngeal Cancer: Therapeutic Assessment

This segment of the report provides insights about the Human Papillomavirus-positive Oropharyngeal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Human Papillomavirus-positive Oropharyngeal Cancer

There are approx. 5+ key companies which are developing the therapies for Human Papillomavirus-positive Oropharyngeal Cancer. The companies which have their Human Papillomavirus-positive Oropharyngeal Cancer drug candidates in the most advanced stage, i.e. phase II include Corvus Pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Human Papillomavirus-positive Oropharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Human Papillomavirus-positive Oropharyngeal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human Papillomavirus-positive Oropharyngeal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human Papillomavirus-positive Oropharyngeal Cancer drugs.

Human Papillomavirus-positive Oropharyngeal Cancer Report Insights

• Human Papillomavirus-positive Oropharyngeal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Human Papillomavirus-positive Oropharyngeal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Human Papillomavirus-positive Oropharyngeal Cancer drugs?
• How many Human Papillomavirus-positive Oropharyngeal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human Papillomavirus-positive Oropharyngeal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Human Papillomavirus-positive Oropharyngeal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Human Papillomavirus-positive Oropharyngeal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Corvus Pharmaceuticals
• Precigen
• PDS Biotechnology
• Dana-Farber Cancer Institute
• Cue Biopharma

Key Products

• Mupadolimab
• PRGN-2009
• PDS0101
• BKM120
• CUE-101

This product will be delivered within 2 business days.